PD1 Inhibitors

Regeneron Pharmaceuticals, Inc. and Sanofi  now market an FDA approved PD1 Inhibitor called  Libtayo®(cemiplimab) for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation. Libtayo is a fully-human monoclonal antibody targeting the immune checkpoint receptor PD-1 (programmed cell death protein-1) and is the first and only treatment specifically approved and available for advanced CSCC in the U.S.